{{Rsnum
|rsid=801114
|Chromosome=1
|position=228862088
|Orientation=plus
|GMAF=0.4867
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 9.8 | 48.2 | 42.0
| HCB | 12.4 | 52.6 | 35.0
| JPT | 12.4 | 53.1 | 34.5
| YRI | 74.1 | 24.5 | 1.4
| ASW | 54.4 | 38.6 | 7.0
| CHB | 12.4 | 52.6 | 35.0
| CHD | 16.5 | 27.5 | 56.0
| GIH | 7.9 | 36.6 | 55.4
| LWK | 65.5 | 31.8 | 2.7
| MEX | 12.1 | 55.2 | 32.8
| MKK | 52.6 | 39.1 | 8.3
| TSI | 12.7 | 48.0 | 39.2
| HapMapRevision=28
}}
2 SNPs located in different regions of chromosome 1 are likely to be associated with increased risk for [[basal cell carcinoma]] (BCC), the most common form of [[skin cancer]]. {{PMID|18849993}}

*each A at [[rs7538876]] yields a 1.28x increased risk of developing BCC (p = 4.4 x 10e-12)
*each G at [[rs801114]] also yields a 1.28x increased odds of developing BCC (p = 5.9 x 10e-12)
*2.68x increased risk of BCC for homozygous carriers of both SNPs

This study was based on an analysis of ~2,000 Icelandic and Eastern European [[skin cancer]] patients (as well as a large number of controls). The authors estimate that approximately 1.6% of all individuals of European ancestry are homozygous for both risk alleles, and thus that percentage of the population is at 2.68x higher risk for BCC compared to individuals who are [[rs7538876]](G;G) and [[rs801114]](T;T). {{PMID|18849993}}

See also:[http://blog.23andme.com/2008/10/13/snpwatch-two-dna-variants-linked-to-basal-cell-carcinoma-the-most-common-form-of-skin-cancer/ 23andMe blog]

{{omim
|desc=BASAL CELL CARCINOMA, MULTIPLE
|id=605462
|rsnum=801114
}}

{{PharmGKB
|RSID=rs801114
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:18849993; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. (Initial Sample Size: 930 cases, 33,117 controls; Replication Sample Size: 1,216 cases, 2,844 controls); (Region: 1q42.13; Reported Gene: RHOU; Risk Allele: rs801114-G) This variant is associated with Cutaneous basal cell carcinoma.
|Drugs=
|Drug Classes=
|Diseases=Carcinoma, Basal Cell
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164740877
}}

{{PharmGKB
|RSID=rs801114
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:18849993
|Annotation=This variant is associated with the risk of basal cell carcinoma.
|Drugs=
|Drug Classes=
|Diseases=Carcinoma, Basal Cell
|Curation Level=Curated
|PharmGKB Accession ID=PA162356001
}}

{{PharmGKB
|RSID=rs801114
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:18849993; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. (Initial Sample Size: 930 cases, 33,117 controls; Replication Sample Size: 1,216 cases, 2,844 controls); (Region: 1q42.13; Reported Gene(s): RHOU; Risk Allele: rs801114-G); (p-value= 0.000000000006).This variant is associated with Basal cell carcinoma (cutaneous).
|Drugs=
|Drug Classes=
|Diseases=Neoplasms
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164740802
}}

{{omim
|id=613058
|rsnum=801114
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs801114
|overall_frequency_n=66
|overall_frequency_d=128
|overall_frequency=0.515625
|n_genomes=43
|n_genomes_annotated=0
|n_haplomes=62
|n_articles=1
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}